Novartis's Diovan gains paediatric indication in EU
This article was originally published in Scrip
Executive Summary
Novartis's bestselling angiotensin II receptor antagonist Diovan (valsartan) has been approved for hypertension in children and adolescents aged six to 18 in the EU.